GSE127948
HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma
Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used unbiased multi-omics and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance. Overall design: Examination of 92.1 uveal melanoma cell lines treates with two different single agent inhibitors and their combination compared to the vehicle control.